Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis (Q45198841)

10 December 2017

Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis (English)

1 reference

10 December 2017

0 references

0 references

0 references

11

1 reference

10 December 2017

Claudia L Ordoñez

1

1 reference

10 December 2017

Noreen R Henig

2

1 reference

10 December 2017

Nicole Mayer-Hamblett

3

1 reference

10 December 2017

Frank J Accurso

4

1 reference

10 December 2017

Jane L Burns

5

1 reference

10 December 2017

James F Chmiel

6

1 reference

10 December 2017

Cori L Daines

7

1 reference

10 December 2017

Ronald L Gibson

8

1 reference

10 December 2017

Sharon McNamara

9

1 reference

10 December 2017

George Z Retsch-Bogart

10

1 reference

10 December 2017

Moira L Aitken

12

1 reference

10 December 2017

language of work or name

English

0 references

publication date

11 September 2003

1 reference

American Journal of Respiratory and Critical Care Medicine

10 December 2017

1 reference

10 December 2017

168

1 reference

10 December 2017

12

1 reference

10 December 2017

1471-1475

1 reference

Current understanding of the inflammatory process in cystic fibrosis: onset and etiology

10 December 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Effect of high-dose ibuprofen in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Inflammatory cytokines in cystic fibrosis lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Safety and use of sputum induction in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Cytokine concentrations and neutrophil elastase activity in bronchoalveolar lavage and induced sputum from patients with cystic fibrosis, mild asthma and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Microbiology of sputum from patients at cystic fibrosis centers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Early airway infection, inflammation, and lung function in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Lower airway inflammation in infants and young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Interleukin-8 Concentrations Are Elevated in Bronchoalveolar Lavage, Sputum, and Sera of Children with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200306-731OC

10.1164/RCCM.200306-731OC

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference